by Thomas Michael | Nov 20, 2019 | Healthcare, News
TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today it has raised €38.75 million ($42.78 million) in a Series B round of funding. This funding round comprises new investors, BNP Paribas...
Recent Comments